Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 17:14:100180.
doi: 10.1016/j.metop.2022.100180. eCollection 2022 Jun.

Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges

Evropi Amanatidou  1 , Anna Gkiouliava  1 , Eva Pella  1 , Maria Serafidi  1 , Dimitrios Tsilingiris  2 , Natalia G Vallianou  3 , Irene Karampela  4 , Maria Dalamaga  5
Affiliations

Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges

Evropi Amanatidou et al. Metabol Open. .

Abstract

Vaccination programs against SARS-CoV-2 constitute the mainstay of public health interventions against the global COVID-19 pandemic. Currently available vaccines have shown 90% or better rates of protection against severe disease and mortality. Barely a year after vaccines became available, the Omicron variant and its unprecedented speed of transmission has posed a new challenge. Overall, Omicron presents increased immune escape, transmissibility, and decreased pathogenicity. Vaccines do not offer a full protection against SARS-CoV-2 acquisition, since "breakthrough" infections may occur in fully vaccinated individuals, who may in turn spread the virus to others. Breakthrough infections may be causally related to the viral profile (viral variant and load, incubation period, transmissibility, pathogenicity, immune evasion), immunity characteristics (mucosal versus systemic immunity, duration of immunity, etc.), host determinants (age, comorbidities, immune status, immunosuppressive drugs) and vaccination properties (platform, antigen dose, dose number, dose interval, route of administration). Determining the rate of breakthrough infections may be challenging and necessitates the conduction of population-based studies regarding vaccine effectiveness as well as neutralizing antibody testing, a surrogate of immune protection. In this review, we analyze the causes of breakthrough infections, their clinical consequences (severity of infection and transmission), methods of determining their incidence as well as challenges and perspectives. Long COVID as well as multi-inflammatory syndrome in adolescents may be significantly reduced in breakthrough infections. The need for universal pancoranavirus vaccines that would aim at protecting against a plethora of SARS-CoV-2 variants as well as emerging variants is discussed. Finally, novel vaccine strategies, such as nasal vaccines, may confer robust mucosal and systemic protection, reducing efficiently transmission.

Keywords: Antibody; Breakthrough infection; COVID-19; Immunity; Neutralizing antibody; Omicron; Pancoronavirus; SARS-CoV-2; Vaccine; Variant; Variant of concern.

PubMed Disclaimer

Conflict of interest statement

No conflict of interest to disclose.

Figures

Fig. 1
Fig. 1
Understanding SARS-CoV-2 breakthrough infections.
Fig. 2
Fig. 2
Potential mechanisms implicated in breakthrough infections. Breakthrough infections may affect transmission of SARS-CoV-2.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dalamaga M., Karampela I., Mantzoros C.S. Commentary: phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19. Metab, Clin Exp. 2020;109:154282. doi: 10.1016/j.metabol.2020.154282. - DOI - PMC - PubMed
    1. Karampela I., Vallianou N.G., Tsilingiris D., Christodoulatos G.S., Muscogiuri G., Barrea L., et al. Panminerva medica; 2021. Could inhaled corticosteroids be the game changers in the prevention of severe COVID-19? A review of current evidence. - DOI - PubMed
    1. Vallianou N.G., Tsilingiris D., Christodoulatos G.S., Karampela I., Dalamaga M. Anti-viral treatment for SARS-CoV-2 infection: a race against time amidst the ongoing pandemic. Metabolism open. 2021;10:100096. doi: 10.1016/j.metop.2021.100096. - DOI - PMC - PubMed
    1. Barda N., Dagan N., Ben-Shlomo Y., Kepten E., Waxman J., Ohana R., et al. Safety of the BNT162b2 mRNA covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385:1078–1090. doi: 10.1056/NEJMoa2110475. - DOI - PMC - PubMed
    1. Tsilingiris D., Vallianou N.G., Karampela I., Liu J., Dalamaga M. Potential implications of lipid nanoparticles in the pathogenesis of myocarditis associated with the use of mRNA vaccines against SARS-CoV-2. Metabolism open. 2022;13:100159. doi: 10.1016/j.metop.2021.100159. - DOI - PMC - PubMed

LinkOut - more resources